BioSpace News Archive

WCG today announced its acquisition of Trifecta Clinical, a proven leader in technology-enabled clinical trial solutions, including its comprehensive site communication platform InvestigatorSpace®, virtual training programs and safety documentation services.

DYSIS Smart Colposcopy is computer-aided cervical imaging that adds the DYSISmap to a standard colposcopic assessment with clinical studies showing that it helps clinicians increase detection of high-grade cervical lesions

The National Resident Matching Program® has released the results of the 2020 Medical Specialties Matching Program.

Micro-Tech Endoscopy USA rounds out the year with yet another product launch in the GI Dilation category.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it will host a research and development call on the Company’s systemic complement regulator programs on Monday, December 14, 2020 at 12:00 pm Eastern Time.

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today provided a clinical update from the company’s ongoing dose-escalation Phase 1 study of STRO-002

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today provided an update on the clinical development and production of mRNA-1273, its vaccine candidate against COVID-19

As part of a national movement to develop treatments and therapies for COVID-19, Intermountain Healthcare researchers are launching a study in Utah to examine the effects of anticoagulants on patients who have tested positive for the novel coronavirus.

Ascletis Pharma Inc. (HKEX:1672) announces today that Phase IIa data demonstrated that ASC22 (Envafolimab) is safe and well tolerated in chronic hepatitis B (CHB) patients and Phase IIb clinical trial has been initiated.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved oral, once-daily ORLADEYO™ (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.